$MRZM | Marizyme, Inc. - DuraGraft Approved for US Markets
"On October 6, Marizyme, Inc. (MRZM) announced a key milestone in its growth strategy, with FDA approval of its flagship DuraGraft (DG) technology for the US market." - Water Tower Research (Water Tower Research)
Key Points:Key milestone in FDA approval. On October 6, Marizyme, Inc. (MRZM) announced a key milestone in its growth strategy, with FDA approval of its flagship DuraGraft (DG) technology for the US market.Improved outcomes when used in cardiac care. DG has been proven to result in significantly improved outcomes and lower costs for cardiac surgery through multiple clinical trials as well as utilization in selected markets in Europe and Asia where adoption has recently accelerated.Reflecting that, YTD DG-driven revenue is already more than double the level of 2022.
Read more: https://www.smartkarma.com/insights/marizyme-inc-duragraft-approved-for-us-markets
$MRZM $RGXTF $VSOLF The Watchlist by The Market Herald Releases New Interviews with Marizyme, Regenx, BuildDirect, and Three Sixty Solar Discussing Their Latest News
https://www.stocktitan.net/news/MRZM/the-watchlist-by-the-market-herald-releases-new-interviews-with-i7eqjniryg5q.html
$MRZM Marizyme, Inc. Announces FDA Clearance for Flagship Product, DuraGraft™
https://www.stocktitan.net/news/MRZM/marizyme-inc-announces-fda-clearance-for-flagship-product-dura-ri4832139833.html
